HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) continues to rise by over 10%, with an expected increase in net profit of up to 4.4 times for the full year. The company has also achieved multiple major external authorizations.

Biocytogen Pharmaceuticals-B(02315) rose by over 10%, reaching an increase of 8.58% at the time of writing, with a price of 45.56 Hong Kong dollars and a trading volume of 66.1952 million Hong Kong dollars. On the news front, Biocytogen Pharmaceuticals recently released a performance forecast for the year 2025, expecting a net profit attributable to shareholders of 162 million to 182 million yuan, an increase of 384.26% to 443.88% year-on-year. The announcement stated that benefiting from the continued expansion of overseas markets, combined with the recovery of the domestic biomedical industry, the company's operating income achieved high-speed growth. The high barriers to entry of its technological advantages ensure that business gross profit remains high, and lean management measures further promote operational efficiency improvement, enabling the company's profitability to rapidly increase. Guolian Minsheng Securities noted that since 2025, the company has reached external agreements with several leading pharmaceutical companies domestically and internationally, and multiple pipelines have received IND approvals. With the advancement of licensed pipelines, the company is expected to receive milestone payments and other income, further opening up growth opportunities. External agreements include the following: in July 2025, the company reached a global license agreement for antibody molecules with BEONE MEDICINES, expanding their cooperation from the whole human antibody platform to the field of antibody molecule licensing; in September 2025, the company signed an agreement with Merck for the authorization of fully human antibodies developed on the RenMice platform, which will be used for the development of antibody conjugate LNP.